-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical News, February 25, recently, the official website of CDE showed that CSPC Ouyi Pharmaceutical's lenalidomide capsules were accepted for listing applications submitted in generic 4 categories
.
According to data from Meinenet, in 2019, the total sales of lenalidomide capsules in China's public medical institutions and China's urban physical pharmacies exceeded 800 million yuan
.
Data show that lenalidomide is a synthetic glutamate derivative, which has the effect of inhibiting angiogenesis and immune regulation
.
Due to the advantages of good therapeutic effect, high safety and convenient administration method, lenalidomide has become the first choice for targeted therapy of multiple myeloma
.
The source of the overall sales of lenalidomide capsules: My Nei.
com database.
According to the data of My Nei.
com, in 2019, it will be sold in Chinese urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminals and cities in China.
The total sales of lenalidomide capsules in the physical pharmacy terminal exceeded 800 million yuan
.
Among them, the terminal sales growth rate of public medical institutions in China is nearly 80%; and the terminal growth rate of physical pharmacies in Chinese cities is even more alarming, exceeding 200%
.
It is worth noting that in recent years, with the efforts of domestic pharmaceutical companies, the market share of original research drugs has gradually declined
.
Source: MED2.
0 China Drug Evaluation Database Currently, there are 5 manufacturers of lenalidomide capsules including Xinji, Chia Tai Tianqing Pharmaceutical Group, Qilu Pharmaceuticals, among them, Chia Tai Tianqing Pharmaceutical Group, Qilu Pharmaceuticals, and Yangtze River Pharmaceuticals The four domestic generic pharmaceutical companies of Beijing Shuanglu Pharmaceutical Group and Beijing Shuanglu Pharmaceutical have all been reviewed
.
Eight companies including CSPC Ouyi Pharmaceutical, Jiangsu Haosen Pharmaceutical, and Changzhou Pharmaceutical Factory have submitted their listing applications, all of which are under review and approval (in the Drug Approval Center)
.
Source: CDE official website, Minet database
.
According to data from Meinenet, in 2019, the total sales of lenalidomide capsules in China's public medical institutions and China's urban physical pharmacies exceeded 800 million yuan
.
Data show that lenalidomide is a synthetic glutamate derivative, which has the effect of inhibiting angiogenesis and immune regulation
.
Due to the advantages of good therapeutic effect, high safety and convenient administration method, lenalidomide has become the first choice for targeted therapy of multiple myeloma
.
The source of the overall sales of lenalidomide capsules: My Nei.
com database.
According to the data of My Nei.
com, in 2019, it will be sold in Chinese urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) terminals and cities in China.
The total sales of lenalidomide capsules in the physical pharmacy terminal exceeded 800 million yuan
.
Among them, the terminal sales growth rate of public medical institutions in China is nearly 80%; and the terminal growth rate of physical pharmacies in Chinese cities is even more alarming, exceeding 200%
.
It is worth noting that in recent years, with the efforts of domestic pharmaceutical companies, the market share of original research drugs has gradually declined
.
Source: MED2.
0 China Drug Evaluation Database Currently, there are 5 manufacturers of lenalidomide capsules including Xinji, Chia Tai Tianqing Pharmaceutical Group, Qilu Pharmaceuticals, among them, Chia Tai Tianqing Pharmaceutical Group, Qilu Pharmaceuticals, and Yangtze River Pharmaceuticals The four domestic generic pharmaceutical companies of Beijing Shuanglu Pharmaceutical Group and Beijing Shuanglu Pharmaceutical have all been reviewed
.
Eight companies including CSPC Ouyi Pharmaceutical, Jiangsu Haosen Pharmaceutical, and Changzhou Pharmaceutical Factory have submitted their listing applications, all of which are under review and approval (in the Drug Approval Center)
.
Source: CDE official website, Minet database
